Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03674814
Recruitment Status : Recruiting
First Posted : September 18, 2018
Last Update Posted : May 13, 2021
Sponsor:
Collaborators:
Corcept Therapeutics
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Chicago

Tracking Information
First Submitted Date  ICMJE August 29, 2018
First Posted Date  ICMJE September 18, 2018
Last Update Posted Date May 13, 2021
Actual Study Start Date  ICMJE October 23, 2018
Estimated Primary Completion Date January 10, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 14, 2018)
  • Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 [ Time Frame: 28 days after start of dosing ]
  • Change in steady-state (C-trough) enzalutamide caused by relacorilant [ Time Frame: 28 days after start of dosing ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 14, 2018)
  • Preliminary anti-cancer activity of relacorilant as measured by prostate specific antigen levels per response evaluation criteria in solid tumors [ Time Frame: 12 weeks after initial start of combination dosing ]
  • Preliminary anti-cancer activity of relacorilant as measured by tumor response per response evaluation criteria in solid tumors [ Time Frame: 12 weeks after initial start of combination dosing ]
  • Assess steady state relacorilant drug levels when given with enzalutamide [ Time Frame: 28 days after start of dosing ]
  • Assess steady state enzalutamide drug levels when given with relacorilant [ Time Frame: 28 days after start of dosing ]
  • Radiographic progression free survival (PFS) of the combination [ Time Frame: Approximately 3 years ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
Official Title  ICMJE A Phase I Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist CORT-125134 (Relacorilant) for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Brief Summary The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).
Detailed Description The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC). Patients will be enrolled in 6 patient cohorts with a 6+3 design and a 28 day DLT period. Doses of relacorilant, enzalutamide will be adjusted based on safety and pharmacokinetics (PK). Once a safe dose with appropriate drug levels (PK) has been established, the cohort will be expanded to a total of 12 patients to refine safety and PK at the recommended phase II dose (RP2D).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Patients will be sequentially enrolled to increasing dose escalation cohorts based on safety and PK.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostate Cancer
Intervention  ICMJE
  • Drug: Enzalutamide
    Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
    Other Name: Xtandi(R)
  • Drug: Relacorilant
    Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
    Other Name: CORT-125134
Study Arms  ICMJE Experimental: Dose Level
Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily.
Interventions:
  • Drug: Enzalutamide
  • Drug: Relacorilant
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 14, 2018)
24
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 10, 2025
Estimated Primary Completion Date January 10, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically or cytologically confirmed prostate cancer with documented metastatic disease
  2. Evidence of castrate testosterone level <50ng/dl (or surgical castration)
  3. Evidence of disease progression:

    • 2 or more new lesions on bone scan or
    • Progressive disease on CT/MRI according to Response Evaluation Criteria in Solid Tumors 1.1 criteria or
    • Rising Prostate Specific Antigen (PSA): PSA evidence for progressive prostate cancer consists of a minimum PSA level of at least 2 ng/ml, which has subsequently risen on at least 2 successive occasions, at least 2 weeks apart.
  4. Prior treatment with at least one line of potent androgen receptor signaling inhibitor (e.g. abiraterone, enzalutamide, apalutamide) in either castration-sensitive or castration-resistant setting.
  5. Any prior therapy for castrate disease is acceptable except prior GR antagonist treatment (e.g. mifepristone or relacorilant).
  6. Any other radiotherapy or radionuclide require 28-day washout prior to first dose of study drug.
  7. Denosumab or zoledronic acid are allowed.
  8. ECOG performance status ≤ 2.
  9. Patients must have normal hepatic function as defined below:

    • Total bilirubin </=1.5 x the upper limit of normal
    • AST(SGOT)/ALT(SGPT) </=2.5 X institutional upper limit of normal
    • Albumin >/=3.0 g/dL
  10. Patients must have normal bone marrow function as defined below:

    • Platelet count (plt) >/= 80,000 /microliter
    • Hemoglobin (Hgb) >/= 9 g/dL
    • Absolute neutrophil count (ANC) >/= 1500
  11. Patients must have normal renal function as defined below:

    • GFR >/= 30 mL/min
  12. Ability to understand and the willingness to sign a written informed consent document.
  13. Patients with active Diabetes Mellitus on glucose lowering medications are eligible provided they agree to and are able to self-monitor daily blood glucose levels due to potential risk of lowering glucose levels on relacorilant.
  14. Male patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration. Two acceptable methods of birth control thus include the following:

    • Condom (barrier method of contraception); AND
    • One of the following is required:

      1. Established use of oral, or injected or implanted hormonal method of contraception by the female partner;
      2. Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner;
      3. Additional barrier method: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female partner;
      4. Tubal ligation in the female partner;
      5. Vasectomy or other procedure resulting in infertility (e.g., bilateral orchiectomy), for more than 6 months.

Exclusion Criteria:

  1. Therapy with other hormonal therapy, including any dose of megestrol acetate (Megace), finasteride (Proscar), dutasteride (Avodart), or any herbal product known to decrease PSA levels (e.g., saw palmetto and PC-SPES), or any systemic corticosteroid within 2 weeks prior to first dose of study drug.

    a.Patients who have been on systemic corticosteroids with prednisone equivalent of 10mg or greater for greater than 3 months immediately prior to participation in this study must have documented ability to tolerate cessation of corticosteroids prior to enrollment.

  2. Inability to swallow capsules or known gastrointestinal malabsorption.
  3. Evidence of visceral disease on imaging in a patient who is an appropriate candidate for cytotoxic chemotherapy (docetaxel or cabazitaxel).
  4. History of other malignancies, with the exception of: adequately treated non-melanoma skin cancer, adequately treated superficial bladder cancer, stage 1 or 2 malignancies who are without evidence of disease, or other cancers curatively treated with no evidence of disease for > 5 years from enrollment.
  5. Blood pressure that is not controlled despite > 2 oral agents (SBP >160 and DBP >90 documented during the screening period with no subsequent blood pressure readings >160/100).
  6. History of seizure disorder or active use of anticonvulsants. Medications used to treat neuropathic pain such as gabapentin or pregabalin are allowed.
  7. Documented history of or current brain metastases due to seizure risk
  8. Serious intercurrent infections or non-malignant medical illnesses that are uncontrolled.
  9. Active psychiatric illness/social situations that would limit compliance with protocol requirements.
  10. NYHA class II, NYHA class III, or IV congestive heart failure (any symptomatic heart failure).
  11. Concurrent therapy with strong inhibitors or inducers of CYP3A4 or CYP2C8 (See Section 9.12below for list of strong inhibitor or inducers) due to concerning possible drug-drug interactions
  12. Presence of concurrent medical conditions requiring systemic glucocorticoids for immunosuppression (e.g. Autoimmune diseases, organ transplantation) that is active and has required glucocorticoids in the last 6 months.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Russell Szmulewitz, MD 773-702-7609 Rszmulew@medicine.bsd.uchicago.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03674814
Other Study ID Numbers  ICMJE IRB18-0152
P50CA180995 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Chicago
Study Sponsor  ICMJE University of Chicago
Collaborators  ICMJE
  • Corcept Therapeutics
  • National Cancer Institute (NCI)
Investigators  ICMJE Not Provided
PRS Account University of Chicago
Verification Date May 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP